Wockhardt shares surged over 8% on June 18, hitting an intraday high of \u20b91,867.90, as the pharma stock continues its strong upward momentum. The stock has now rallied nearly 45% over the past month, making it one of the standout performers in the pharmaceutical sector.<\/p>\n
The sharp rise in Wockhardt\u2019s stock price came on the back of heavy trading volumes, reflecting strong investor interest. Over 35 lakh shares worth nearly \u20b9640 crore were traded in just the first three hours on June 18, well above the stock\u2019s 10-day average volume.<\/p>\n
\nThis surge in volumes points to growing market optimism around Wockhardt\u2019s near-term prospects.<\/p>\n<\/blockquote>\n
Touches 52-Week High, Then Recovers Again<\/h3>\n
Wockhardt shares had earlier touched a 52-week high of \u20b91,868.80 on June 12. While the stock experienced some correction in the sessions that followed, it bounced back sharply on June 18, supported by strong fundamentals and investor confidence.<\/p>\n
Zaynich Antibiotic in Focus<\/h3>\n
One of the major drivers behind the stock\u2019s performance is investor anticipation around Zaynich, a breakthrough antibiotic being developed by Wockhardt to combat drug-resistant infections.<\/p>\n
Earlier this month, the company confirmed plans to file a New Drug Application (NDA) for Zaynich with the US FDA in Q2 of FY25.<\/p>\n
\n\u201cThere is a very high certainty that we should be able to market the product in the US by 2026-27,\u201d said Chairman Habil Khorakiwala at an event celebrating 25 years of Wockhardt\u2019s listing on the NSE.<\/p>\n<\/blockquote>\n
He also added that Indian regulatory approval is expected by early next year, with the product likely to hit the domestic market by mid-2026.<\/p>\n
Financial Turnaround in Q4FY25<\/h4>\n
Wockhardt\u2019s recent stock momentum is also backed by improving financials. In Q4FY25, the company\u2019s net loss narrowed to \u20b945 crore, a significant improvement from the \u20b9177 crore loss a year ago.<\/p>\n
\n
- \n
Revenue rose 6% YoY to \u20b9743 crore, compared to \u20b9700 crore in Q4FY24.<\/p>\n<\/li>\n
- \n
The company posted a positive EBITDA of \u20b964 crore, a dramatic turnaround from an EBITDA loss of \u20b9103 crore in the same quarter last year.<\/p>\n<\/li>\n<\/ul>\n
\nThis return to positive operating margins signals a recovery in performance and better cost management.<\/p>\n<\/blockquote>\n
What\u2019s Next for Wockhardt?<\/h4>\n
With Zaynich\u2019s launch timeline now becoming clearer, and the company showing strong signs of operational recovery, investors appear optimistic about Wockhardt\u2019s growth story. The stock remains in focus for both retail and institutional players looking for exposure in the pharmaceutical innovation space.<\/p>\n
Know more about us-<\/strong>
\nNiftyTrader<\/a>
\nGiftNifty<\/a>
\nBSE Option Chain<\/a>
\nNSE Option Chain<\/a>
\nIPO\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Wockhardt shares surged over 8% on June 18, hitting an intraday high of \u20b91,867.90, as the pharma stock continues its strong upward momentum. The stock has now rallied nearly 45% over the past month, making it one of the standout performers in the pharmaceutical sector. High Trading Volumes Fuel the Rally The sharp rise in […]<\/p>\n","protected":false},"author":2,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[615],"tags":[],"ppma_author":[1329],"class_list":{"0":"post-10613","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stock-market-news"}," _eael_post_view_count":0,"authors":[{"term_id":1329,"user_id":2,"is_guest":0,"slug":"snehagandhi","display_name":"Sneha Gandhi","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/10\/Sneha-Gandhi.jpeg","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/10\/Sneha-Gandhi.jpeg"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/10613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=10613"}],"version-history":[{"count":5,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/10613\/revisions"}],"predecessor-version":[{"id":10629,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/10613\/revisions\/10629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/10614"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=10613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=10613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=10613"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=10613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}